Washington University School of Medicine in St. Louis

Home/Tag:Washington University School of Medicine in St. Louis

Stem cells edited to fight arthritis

Goal is vaccine that targets inflammation in joints by Jim Dryden•April 27, 2017 ELLA MARUSHCHENKO Using CRISPR technology, a team of researchers led by Farshid Guilak, PhD, at Washington University School of Medicine in St. Louis, rewired stem cells' genetic circuits to produce an anti-inflammatory arthritis drug when the cells encounter inflammation. The technique eventually

Antibody helps detect protein implicated in Alzheimer’s, other diseases

May lead to novel ways to diagnose, monitor brain injury by Tamara Bhandari•April 19, 2017 HUY MACH Researchers use mouse brains (above) to study ways to measure the brain protein tau, which plays a role in neurodegenerative diseases such as Alzheimer's. A team led by scientists at Washington University School of Medicine in St. Louis

Rogue breast tumor proteins point to potential drug therapies

Such treatment options are missed by genomic sequencing By Julia Ezangelou Strait March 28, 2017 For patients with difficult-to-treat cancers, doctors increasingly rely on genomic testing of tumors to identify errors in the DNA that indicate a tumor can be targeted by existing therapies. But this approach overlooks another potential marker — rogue proteins — that may

New immunotherapy for leukemia shows promise in small clinical trial

'Training' immune cells boosts effectiveness in patients with AML By Julie Evangelou Strait September 21, 2016 A new type of immunotherapy shows promise against cases of acute myeloid leukemia (AML) that recur after treatment or that never respond to therapy in the first place. A small clinical trial at Washington University School of Medicine in St. Louis

$4 million grant expands major study to find Alzheimer’s prevention treatments

Investigators will accelerate drug testing, develop new diagnostic measures by Tamara Bhandari • June 21, 2016 JUDY MARTIN FINCH Dean DeMoe, a participant in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) study at Washington University, receives AV1451 — a radiopharmaceutical — from imaging technologist Holly Karsch. AV1451 binds to tau protein in the brain. Washington University

New clues found to immune system’s misfiring in autoimmune diseases

Gene variants mapped to DNA regions that regulate immune cells By Tamara Bhandari June 2, 2016 Genetic master switches that turn up – or down – the activity of specific types of immune cells have been identified by a team of researchers at Washington University School of Medicine in St. Louis. The regions of DNA that make

Surgeons test technology with potential to expand lung transplant donor pool

Device designed to recondition lungs, keep organs thriving outside body by Kristina Sauerwein•April 6, 2016 JERRY NAUNHEIM JR. Organ transplant patient Michele Coleman receives a follow-up exam a few months after surgeons at Washington University School of Medicine in St. Louis gave her a new set of lungs. As he conducted the check-up, Ramsey Hachem,

New clues identified in childhood cancer syndrome

Findings may help doctors determine which issues are likely to manifest in those with NF1 By Jessica L. Williams March 30, 2016 New research from David Gutmann, MD, PhD, may help doctors determine which medical issues are likely to manifest in patients with the inherited cancer syndrome neurofibromatosis type 1 (NF1). The findings indicate that

Longer-lived imaging agents could hasten Alzheimer’s research

Chemist hopes to force Alzheimer's to show its hand By Diana Lutz Feb. 29, 2016 In the past few years, despite the best efforts of scientists and medical researchers, drug after drug designed to slow or stop the progression of Alzheimer’s disease has failed in clinical trials. Some had no effect on the progression of the disease,

$11.9 million from NIH funds glaucoma study

Researchers to evaluate effectiveness of earlier efforts to prevent, delay blinding eye disease by Jim Dryden•February 26, 2016 ROBERT BOSTON PHOTO Michael A. Kass, MD, will lead a nationwide study to determine whether efforts to prevent or delay the onset of glaucoma have been effective over the course of two decades. Researchers at Washington University